Related references
Note: Only part of the references are listed.Bisphosphonates: The first 40 years
R. Graham G. Russell
BONE (2011)
Bisphosphonates' antitumor activity: An unravelled side of a multifaceted drug class
Philippe Clezardin
BONE (2011)
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
Nicolas Mottet et al.
EUROPEAN UROLOGY (2011)
Ras Inhibition and the Survival Benefit Favoring Zoledronic Acid Compared With Denosumab in Patients With Multiple Myeloma
Steven M. Sorscher et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Emerging Therapies to Prevent Skeletal Morbidity in Men With Prostate Cancer
Philip J. Saylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Zoledronic Acid Induces Autophagic Cell Death in Human Prostate Cancer Cells
Ji-Fan Lin et al.
JOURNAL OF UROLOGY (2011)
Statin Medication Use and the Risk of Biochemical Recurrence After Radical Prostatectomy Results From the Shared Equal Access Regional Cancer Hospital (SEARCH) Database
Robert J. Hamilton et al.
CANCER (2010)
Farnesyl diphosphate synthase attenuates paclitaxel-induced apoptotic cell death in human glioblastoma U87MG cells
Im Sun Woo et al.
NEUROSCIENCE LETTERS (2010)
A Clinical Review of Statins and Cancer: Helpful or Harmful?
Michael J. Gonyeau et al.
PHARMACOTHERAPY (2010)
Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
Debashis Sarker et al.
CLINICAL CANCER RESEARCH (2009)
Reduced Expression of the Mevalonate Pathway Enzyme Farnesyl Pyrophosphate Synthase Unveils Recognition of Tumor Cells by Vγ9Vδ2 T Cells
Jianqiang Li et al.
JOURNAL OF IMMUNOLOGY (2009)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
No Effect of Statins on Biochemical Outcomes After Radiotherapy for Localized Prostate Cancer
Daniel E. Soto et al.
UROLOGY (2009)
Statin use and prostate cancer risk in a large population-based setting
Denise M. Boudreau et al.
CANCER CAUSES & CONTROL (2008)
Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies
Stefanos Bonovas et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients
Gary D. Friedman et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2008)
Cholesterol-lowering drugs and advanced prostate cancer incidence in a large US cohort
Eric J. Jacobs et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer
Claire Morgan et al.
ACTA ONCOLOGICA (2007)
Tissue microarrays: applications in urological cancer research
A. S. Merseburger et al.
WORLD JOURNAL OF UROLOGY (2006)
Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells
HL Neville-Webbe et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation
JP Coxon et al.
BJU INTERNATIONAL (2004)
Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis
M Notarnicola et al.
ONCOLOGY (2004)
Farnesyl diphosphate synthase is abundantly expressed and regulated by androgen in rat prostatic epithelial cells
F Jiang et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2001)
Share Paper
